480 Biomedical Inc. has been awarded Phase II funding from the National Heart, Lung, and Blood Institute (NHLBI) for further development of a scaffold to treat pulmonary artery stenosis (PAS). The company will be awarded $1 million to improve the bioresorbable, self-expanding scaffold to help treat cardiovascular stenosis in children with growing blood vessels. Currently stents used in procedures to treat PAS are not suitable for pediatric patients due to growth. They often have to be surgically removed to address arterial obstruction and to create blood flow.

The scaffold 480 Biomedical is currently working on has the strength of a balloon-expandable metal stent to ensure vessels stay open for a long period of time before resorbing. Essential for pediatrics, the scaffold can also be delivered through a small catheter. A prototype with strength similar to a metal stent using Stanza scaffold technology has been developed, featuring tissue absorption over the course of one year and minimally invasive delivery through a flexible catheter. NHLBI will continue clinical studies of the product.